                         SEQUENCE LISTING

<110>  THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
 
<120>  ENGINEERED EXOSOMES FOR MEDICAL APPLICATIONS

<130>  19-1282-WO

<150>  62/698,650
<151>  2018-07-16

<160>  17    

<170>  PatentIn version 3.5

<210>  1
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Collagen-derived peptide

<400>  1

Asp Gly Glu Ala 
1               


<210>  2
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Collagen-derived peptide

<400>  2

Gly Phe Pro Gly Glu Arg 
1               5       


<210>  3
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cell surface binding factor of the disclosure

<400>  3

Ile Pro Val Ser Leu Arg Ser Gly Ala Gly Pro Glu Gly 
1               5                   10              


<210>  4
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cell surface binding factor of the disclosure

<400>  4

Gly Pro Leu Gly Leu Ala Gly Gly Glu Arg Asp Gly 
1               5                   10          


<210>  5
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cell surface binding factor of the disclosure

<400>  5

Gly Phe Leu Gly 
1               


<210>  6
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cell surface binding factor of the disclosure

<400>  6

Gly Pro Met Gly Ile Ala Gly Gln 
1               5               


<210>  7
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cell surface binding factor domain of the disclosure including 
       cleavable

<400>  7

Gly Gly Gly Gly Ile Pro Val Ser Leu Arg Ser Gly Ala Gly Pro Glu 
1               5                   10                  15      


Gly Asp Gly Glu Ala Tyr 
            20          


<210>  8
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  miRNA target sequence that directs exosomal sorting

<400>  8

Gly Gly Gly Gly Arg Gly Asp Tyr 
1               5               


<210>  9
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide used to provide cell surface binding factor of the 
       disclosure

<400>  9

Gly Gly Ala Gly 
1               


<210>  10
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide used to provide cell surface binding factor of the 
       disclosure

<400>  10

Gly Gly Gly Gly Asp Gly Glu Ala Tyr 
1               5                   


<210>  11
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide used to provide cell surface binding factor of the 
       disclosure

<400>  11

Gly Phe Pro Gly Glu Arg 
1               5       


<210>  12
<211>  25
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  has-miR15a-5p primer

<400>  12
gggtagcagc acataatggt ttgtg                                             25


<210>  13
<211>  25
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  has-miR15b-5p primer

<400>  13
gggtagcagc acatcatggt ttaca                                             25


<210>  14
<211>  24
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  has-miR16-5p primer

<400>  14
ggtagcagca cgtaaatatt ggcg                                              24


<210>  15
<211>  24
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  has-miR424-5p primer

<400>  15
ggcagcagca attcatgttt tgaa                                              24


<210>  16
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  has-miR497-5p primer

<400>  16
cagcagcaca ctgtggtttg t                                                 21


<210>  17
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  has-miR3960 primer

<400>  17
gcggaggcgg gggaaaaa                                                     18


